[go: up one dir, main page]

MX2016016039A - PHARMACEUTICAL FORMULATION TO REDUCE THE FREQUENCY OF MICTION AND METHOD FOR USE .. - Google Patents

PHARMACEUTICAL FORMULATION TO REDUCE THE FREQUENCY OF MICTION AND METHOD FOR USE ..

Info

Publication number
MX2016016039A
MX2016016039A MX2016016039A MX2016016039A MX2016016039A MX 2016016039 A MX2016016039 A MX 2016016039A MX 2016016039 A MX2016016039 A MX 2016016039A MX 2016016039 A MX2016016039 A MX 2016016039A MX 2016016039 A MX2016016039 A MX 2016016039A
Authority
MX
Mexico
Prior art keywords
frequency
miction
reduce
pharmaceutical formulation
urination
Prior art date
Application number
MX2016016039A
Other languages
Spanish (es)
Inventor
A Dill David
j rauscher Frank
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of MX2016016039A publication Critical patent/MX2016016039A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen métodos y composiciones para reducir la frecuencia de micción. Los métodos comprenden administrar a un sujeto que tiene una condición que genera una frecuencia no deseada de micción una cantidad eficaz de una composición farmacéutica que comprende uno o más inhibidores de la vía de prostaglandinas. Las composiciones farmacéuticas comprenden uno o más inhibidores de la vía de las prostaglandinas y un transportador farmacéuticamente aceptable.Methods and compositions for reducing the frequency of urination are described. The methods comprise administering to an individual having a condition that generates an unwanted frequency of urination an effective amount of a pharmaceutical composition comprising one or more prostaglandin pathway inhibitors. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier.

MX2016016039A 2014-06-06 2014-06-06 PHARMACEUTICAL FORMULATION TO REDUCE THE FREQUENCY OF MICTION AND METHOD FOR USE .. MX2016016039A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/041378 WO2015187183A1 (en) 2014-06-06 2014-06-06 Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
MX2016016039A true MX2016016039A (en) 2017-08-24

Family

ID=54767122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016039A MX2016016039A (en) 2014-06-06 2014-06-06 PHARMACEUTICAL FORMULATION TO REDUCE THE FREQUENCY OF MICTION AND METHOD FOR USE ..

Country Status (9)

Country Link
EP (1) EP3151834A4 (en)
JP (1) JP2017516832A (en)
KR (1) KR20170010440A (en)
CN (1) CN106714805A (en)
AU (1) AU2014396189A1 (en)
MX (1) MX2016016039A (en)
RU (1) RU2016152226A (en)
SG (1) SG11201610383YA (en)
WO (1) WO2015187183A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
RU2018126368A (en) * 2015-12-18 2020-01-20 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи COMPOSITION FOR REDUCING URINARY FREQUENCY, METHOD FOR PRODUCING AND USE
JP2019031556A (en) * 2018-10-31 2019-02-28 ウェルズリー ファーマスーティカルズ、エルエルシー Pharmaceutical formulations for reducing urination frequency and methods of use thereof
WO2021154974A1 (en) * 2020-01-30 2021-08-05 The Regents Of The University Of California Screening for inhibitors of prostaglandin e synthase 3 useful for treatment of prostate cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4421697A (en) * 1996-09-19 1998-04-14 American Home Products Corporation Method of treating urinary incontinence
EP1447096A1 (en) * 2001-11-19 2004-08-18 Ono Pharmaceutical Co., Ltd. Remedies for urinary frequency
MXPA04008037A (en) * 2002-02-19 2004-11-26 Pharmacia Corp Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence.
WO2006102029A2 (en) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
CA2856673C (en) * 2012-01-04 2018-08-21 Wellesley Pharmaceuticals, Llc Use of acetaminophen for reducing the frequency of urination
CA2856677A1 (en) * 2012-01-04 2013-07-11 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
CN104302284A (en) * 2012-03-19 2015-01-21 韦尔斯利医药有限公司 Extended release formulations for alleviating urinary frequency and methods of use thereof

Also Published As

Publication number Publication date
EP3151834A1 (en) 2017-04-12
JP2017516832A (en) 2017-06-22
CN106714805A (en) 2017-05-24
RU2016152226A (en) 2018-07-09
KR20170010440A (en) 2017-01-31
EP3151834A4 (en) 2018-01-03
WO2015187183A1 (en) 2015-12-10
AU2014396189A1 (en) 2016-12-22
RU2016152226A3 (en) 2018-07-09
SG11201610383YA (en) 2017-02-27

Similar Documents

Publication Publication Date Title
AR121273A2 (en) ENZYMATIC INHIBITORS FOR USE IN MEDICINE AND PHARMACEUTICAL COMPOSITION THAT COMPRISES THEM
CL2020001218A1 (en) Useful compounds to inhibit cdk7.
CO2022003782A2 (en) Kras g12d inhibitors
CO2020007244A2 (en) Kras g12c inhibitors
DOP2019000005A (en) 3-METIL PIRAZINAS 2,5-DISUSTITUIDAS AND 3-METIL PIRAZINAS 2,5,6-TRISUSTITUIDAS AS ALLOSTERIC INHIBITORS OF SHP2
CL2016000508A1 (en) Compounds derived from substituted (2-methyl-3-phenylphenyl) methoxy, interaction inhibitors pd-1 / protein pd-l1 / protein; pharmaceutical composition comprising them; and its use to treat an infectious disease or cancer.
CL2017000902A1 (en) Ror-gamma inhibitor dihydropyrrolopyridines
ECSP18040250A (en) COMPOSITIONS AND METHODS TO INHIBIT ARGINASE ACTIVITY
EA201591591A1 (en) COMPOUNDS OF CARBAZOLE APPLIED AS Bromodomain Inhibitors
CO6761389A2 (en) Nampt and rock inhibitors
GT201600147A (en) DERIVATIVE COMPOUNDS AND COMPOSITIONS OF N-AZASPIROCICLOALCANO N-HETEROARIL REPLACED TO INHIBIT THE ACTIVITY OF SHP2
MX2017004471A (en) Triazolopyridine compounds and methods for the treatment of cystic fibrosis.
CL2018000688A1 (en) Heterocyclic compounds containing benzylamine and compositions useful against mycobacterial infection
EA201692249A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
EA201692265A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
DOP2014000098A (en) 2-THIOPIRIMIDINONES
MX2017013875A (en) CERTAIN INHIBITORS OF PROTEIN QUINASA.
MX2017001352A (en) PIRROLIDINONE DERIVATIVES AS INHIBITORS OF METIONIN AMINOPEPTIDASE 2 (METAP-2).
SV2017005466A (en) PIRAZOLPIRIDINAMINS AS INHIBITORS OF MKNK1 AND MKNK2
MX2017013137A (en) Chromene derivatives as phoshoinositide 3-kinases inhibitors.
MX2017011018A (en) Inhibition of olig2 activity.
EA201791807A1 (en) NEW TRITERPENON WITH C-3 WITH REVERSE AMIDIC DERIVATIVES WITH C-17 AS HIV INHIBITORS
MX2016016039A (en) PHARMACEUTICAL FORMULATION TO REDUCE THE FREQUENCY OF MICTION AND METHOD FOR USE ..
CO2018002440A2 (en) Useful compounds to inhibit ror-gamma-t
MX2016015961A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE DIHOMO-GAMMA-LYLENEIC ACID (DGLA) AND USE OF THE SAME.